Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H16O5 |
InChIKeyNEZONWMXZKDMKF-SNVBAGLBSA-N |
CAS Registry517-89-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 11 Aug 2024 |